A Phase 2 Study of HB0017 in Psoriasis Patients

Summary

This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects

Timeline

Start

2024-09-30

Primary completion

2025-04-30

Completion

2026-01-30

Drugs

Indications